Samsung Biologics' $2 Billion Rights Offering Oversubscribed
By Kwanwoo Jun
Samsung Biologics' $2 billion rights offering was oversubscribed, reflecting solid demand for the South Korean biopharmaceutical company's new shares.
The company received bids for 11.9 million shares, compared with 2.3 million shares offered during the Nov. 12-13 subscription period, according to a regulatory filing Monday.
Samsung Biologics priced the shares at 1,174,000 won each, seeking to raise about 2.7 trillion won, equivalent to $2.02 billion, it said. The shares are scheduled to begin trading at the end of the month.
The company said in August that the share sale was intended to help finance its planned acquisition of Swiss contract development and manufacturing organization PolyPeptide Group.
Samsung Biologics announced an all-cash offer in July to acquire PolyPeptide for about 2.7 trillion won.
The acquisition is expected to expand Samsung Biologics' portfolio beyond antibodies and antibody-drug conjugates into peptide-based therapeutics, the company said, positioning it to address growing global demand for a wider range of therapeutic modalities.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
November 16, 2026 01:41 ET (06:41 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

